CAR T-cell therapy with or without radiation for advanced prostate cancer
Tests modified immune T cells, with or without radiation, in men with spreading prostate cancer.
Key facts
- Who runs it
- City of Hope Medical Center
- Where
- Duarte, United StatesSee the site
- Trial code
- Registry title
- PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 21 people, planned
- Started
- 9 Oct 2024
- Expected to end
- 11 Nov 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
- Biopsy
- Biospecimen Collection
- Bone Scan
- Computed Tomography
- External Beam Radiation Therapy
- Leukapheresis
- Lymphodepletion Therapy
- Record updated
- 9 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 18 or older whose prostate cancer has spread and keeps growing despite hormone-lowering treatment, and whose tumor shows the PSCA marker.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Metastatic castration-resistant prostate cancer (cancer that has spread and keeps growing despite testosterone below 50 ng/dL). The disease must have progressed during treatment with at least one advanced hormone therapy such as abiraterone or enzalutamide.
- Earlier treatment
- Must have had at least one advanced androgen targeted therapy (e.g., abiraterone or enzalutamide). If chemotherapy was given, at least 2 weeks must pass before leukapheresis. Earlier radiotherapy is allowed if it was finished more than 14 days before leukapheresis and was not given to the only site of disease. Must have recovered from side effects of earlier cancer treatment to grade 1 or less (hair loss excepted).
- Biomarker or test result
- Tumor must be PSCA-positive, checked by the City of Hope pathology laboratory. For plan 2, 1 to 3 metastatic lesions not previously irradiated are needed.
Main reasons for not taking part
- Taking systemic steroids or long-term immunosuppressant medicines
- Known HIV, hepatitis B or hepatitis C infection
- Active infection needing antibiotics
- Another cancer, with some exceptions such as treated skin cancers
- Stroke or bleeding in the brain within 6 months before screening
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Documented informed consent of the participant and/or legally authorized representative (brown); Assent, when appropriate, will be obtained per institutional guidelines; Note: For research participants who do not speak English, a short form consent may be used with a City of Hope (COH) certified interpreter/translator to proceed with screening and leukapheresis, while the request for a translated main consent is processed. However, the research participant is allowed to proceed with lymphodepletion and CAR T cell infusion only after the translated main consent form is signed
- Agreement to allow the use of archival tissue from diagnostic tumor biopsies; If unavailable, exceptions may be granted with study principal investigator (PI) approval
- Age: >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2 or Karnofsky Performance Status (KPS) >= 70%
- Documented castration resistant prostate cancer (mCRPC) (Note: castration will be defined by a testosterone < 50 ng/dL achieved by orchiectomy or luteinizing hormone-releasing hormone [LHRH] agonist/antagonist therapy); Documented PSCA+ tumor expression as evaluated by the COH Pathology Clinical Trials Specimen Qualification Laboratory (CTSQL); Fresh or archival biopsy samples may be tested for PSCA expression during screening for eligibility purposes. The results from soft tissue biopsies will be used to confirm eligibility for participants who have a soft-tissue lesion biopsy obtained, but bone biopsy staining results will not impact eligibility since immunohistochemistry (IHC) staining for PSCA has not been optimized in bone specimens. Subjects who undergo bone biopsy on study will be qualified based on the archival tissue result; Progression of disease manifest by one of the following means during treatment with at least one advanced androgen targeted therapy (e.g., abiraterone or enzalutamide):; Rising prostate specific antigen (PSA) documented on 2 occasions at least 7 days apart, with absolute increase > 2 ng/dL despite testosterone < 50 OR; Radiographic evidence of new metastatic foci on CT or bone scan, or soft tissue progression by Response Evaluation Criteria in Solid Tumors (RECIST); For treatment plan 2, subjects must have at least one and up to 3 metastatic lesions which have not previously been radiated and which is safe for treatment with radiation 16 gray (Gy) in 2 fractions
- Fully recovered from the acute toxic effects (except alopecia) to =< grade 1 to prior anti-cancer therapy
- If there has been prior chemotherapy, at least 2 weeks must have elapsed prior to leukapheresis
- Prior radiotherapy is allowed provided it was not administered to the only evaluable site of disease and was completed > 14 days prior to leukapheresis
- No known contraindications to leukapheresis, steroids or tocilizumab
- Absolute neutrophil count (ANC) >= 1,000/mm\^3 (within 42 days prior to enrollment); NOTE: Growth factor is not permitted within 14 days of ANC assessment
- Platelets >= 100,000/mm\^3 (within 42 days prior to enrollment) NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment
- Total serum bilirubin =< 2.0 mg/dL (within 42 days prior to enrollment); Patients with Gilbert syndrome may be included if their total bilirubin is =< 3.0 x upper limit of normal (ULN) and direct bilirubin =< 1.5 x ULN
- Aspartate aminotransferase (AST) =< 2.5 x ULN (within 42 days prior to enrollment)
- Alanine aminotransferase (ALT) =< 2.5 x ULN (within 42 days prior to enrollment)
- Creatinine clearance of >= 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula (within 42 days prior to enrollment)
- Corrected QT interval (QTc) =< 480 ms; Note: to be performed within 28 days prior to day 1 of protocol therapy
- Cardiac function (12 lead- electrocardiogram [ECG]) without acute abnormalities requiring investigation or intervention (within 42 days prior to enrollment)
- Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin [RPR]); If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed OR; If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable; Note infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy
- Meets other institutional and federal requirements for infectious disease titer requirements; Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy
- Agreement by males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy; Childbearing potential defined as not being surgically sterilized
Who cannot take part
- Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. Physiologic replacement of steroids (prednisone =< 7.5 mg /day, or hydrocortisone =< 20 mg /day) is allowed
- Subjects with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, including seizure disorder
- History of stroke or intracranial hemorrhage within 6 months prior to screening
- Subjects with clinically significant arrhythmia or arrhythmias not stable on medical management within two weeks of screening
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
- Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia
- Clinically significant uncontrolled illness
- Active infection requiring antibiotics
- Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection
- Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
- History of other malignancies, except for malignancy surgically resected (or treated with other modalities) with curative intent, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; non-muscle invasive bladder cancer; malignancy treated with curative intent with no known active disease present for >= 3 years
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Where in United States
- City of Hope Medical CenterDuarte, United StatesContact: Tanya B. DorffTaking people
About the trial
What the trial wants to find out
This phase Ib trial tests the safety, side effects, and best dose of autologous anti-prostate stem cell antigen (PSCA)-chimeric antigen receptor (CAR)-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (PSCA-CAR T cells), plus or minus radiation, in treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Castration-resistant prostate cancer continues to grow and spread despite the surgical removal of the testes or medical intervention to block androgen production. CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving PSCA-targeting CAR T-cells, with or without radiation, may kill more tumor cells in men with castration-resistant prostate cancer.
The 2 groups in the trial
- Treatment plan I (PSCA CAR T-cells)Treatment being tested
Patients undergo leukapheresis and lymphodepletion and receive PSCA-CAR T cells IV up to 3 times on study. Patients undergo bone scan, CT scan, tumor biopsy, and collection of blood, stool, and urine samples throughout the trial.
Treatment: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Leukapheresis, and Lymphodepletion Therapy
- Treatment plan II (PSCA CAR T-cells, radiation)Treatment being tested
Patients undergo leukapheresis, radiation in 2 doses, and lymphodepletion, and receive PSCA-CAR T cells IV up to 3 times on study. Patients undergo bone scan, CT scan, tumor biopsy, and collection of blood, stool, and urine samples throughout the trial.
Treatment: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Leukapheresis, and Lymphodepletion Therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1b Study Evaluating Combinations With PSCA-Targeting Chimeric Antigen Receptor (CAR)-T Cells for Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
- Plain-language title
- CAR T-cell therapy with or without radiation for advanced prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 November 2026